Found 37 resultsAuthor Title [ Year]
Filters: First Letter Of Last Name is P and Author is Beth A Payne [Clear All Filters]
Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004..
Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62..
The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120..
Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714..
PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597..
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011;377(9761):219-27..
The role of platelet counts in the assessment of inpatient women with preeclampsia. J Obstet Gynaecol Can. 2011;33(9):900-8..
The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81..
Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-Eclampsia Monitoring, Prevention and Treatment) project. J Obstet Gynaecol Can. 2012;34(10):917-926..
An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens. 2013;3(3):166-71..
Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8..
Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223..
Development of mHealth applications for pre-eclampsia triage. IEEE J Biomed Health Inform. 2014;18(6):1857-64..
Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163..
Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210-8; discussion 1220..
Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014;179:58-62..
A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med. 2014;11(1):e1001589..
Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can. 2014;36(10):870-877..
Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24..
Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21..
Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5..
Usability and Feasibility of PIERS on the Move: An mHealth App for Pre-Eclampsia Triage. JMIR Mhealth Uhealth. 2015;3(2):e37..
The Usefulness of the APACHE II Score in Obstetric Critical Care: A Structured Review. J Obstet Gynaecol Can. 2016;38(10):909-918..
External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension. 2017;69(4):705-711..
Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623..
Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension. 2017;70(6):1228-1237..
A process evaluation plan for assessing a complex community-based maternal health intervention in Ogun State, Nigeria. BMC Health Serv Res. 2017;17(1):238..
Reverse innovation in maternal health. Obstet Med. 2017;10(3):113-119..
Validating the Performance of the Modified Early Obstetric Warning System Multivariable Model to Predict Maternal Intensive Care Unit Admission. J Obstet Gynaecol Can. 2017;39(9):728-733.e3..
Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension. 2018;71(4):659-665..
Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) clinical risk prediction model. Crit Care. 2018;22(1):278..
Health and socio-demographic profile of women of reproductive age in rural communities of southern Mozambique. PLoS One. 2018;13(2):e0184249..
Prediction of adverse maternal outcomes from pre-eclampsia and other hypertensive disorders of pregnancy: A systematic review. Pregnancy Hypertens. 2018;11:115-123..
The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. PLoS Med. 2019;16(4):e1002783..
Protocol 13PRT/9313:The Community Level Interventions for Pre-eclampsia (CLIP) Trials: four prospective cluster randomised controlled trials comparing a package of interventions directed towards improving maternal and perinatal outcomes related to pre-ecl [Internet]. 2019 . https://clinicaltrials.gov/ct2/show/study/NCT01911494?term=01911494&rank=1.
Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia. Pregnancy Hypertens. 2019;15:42-50..